Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Cmax (pharmacology)

From Wikipedia, the free encyclopedia
(Redirected fromPeak (pharmacology))

Peak concentration of a drug in a body compartment
For other uses, seeCmax (disambiguation).

Cmax is the maximum (or peak)serumconcentration that a drug achieves in a specifiedcompartment or test area of the body after the drug has been administered and before the administration of a second dose.[1] It is a standard measurement inpharmacokinetics.

Description

[edit]

Cmax is the opposite ofCmin, which is the minimum (or trough) concentration that a drug achieves after dosing. The related pharmacokinetic parametertmax is the time at which theCmax is observed.[2]

After an intravenous administration,Cmax andtmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration,Cmax andtmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject.[3]

Short term drugside effects are most likely to occur at or near theCmax, whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above theCmin.[citation needed]

TheCmax is often measured in an effort to showbioequivalence (BE) between a generic and innovator drug product.[4] According to the FDA, drug qualitybioavailability (BA) and BE rely on pharmacokinetic measurements such asAUC andCmax that are reflective of systemic exposure.[5]

See also

[edit]

References

[edit]
  1. ^Tracy TS (2004). "Pharmacokinetics". In Stitzel RE, Craig CF (eds.).Modern pharmacology with clinical applications. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 49.ISBN 978-0-7817-3762-3.
  2. ^Newlands A (2006)."Statistics and Pharmacokinetics in Clinical Pharmacology Studies"(PDF).SAS Conference Proceedings: Pharmaceutical Users Software Exchange. Archived fromthe original(PDF) on 2013-11-13.
  3. ^Urso R, Blardi P, Giorgi G (March 2002). "A short introduction to pharmacokinetics".European Review for Medical and Pharmacological Sciences.6 (2–3):33–44.PMID 12708608.
  4. ^Midha KK, Rawson MJ, Hubbard JW (October 2005). "The bioequivalence of highly variable drugs and drug products".International Journal of Clinical Pharmacology and Therapeutics.43 (10):485–498.doi:10.5414/cpp43485.PMID 16240706.
  5. ^"Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations".Guidance for Industry. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration. Retrieved18 February 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cmax_(pharmacology)&oldid=1323047242"
Category:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp